<p>Merit Financial Group LLC 在最近向證券交易委員會的披露中表示，在第三季度將其在雅培（NYSE:ABT - 免費報告）股票的持有量提高了 32.7%。該公司在季度內購買了 20,035 股後，持有 81,264 股這家醫療產品製造商的股票。根據其最近的 SEC 文件，Merit Financial Group LLC 在雅培的持股價值為 10,884,000 美元。</p>
<p>獲取 <strong>雅培</strong> 的提醒：</p>
<ul>
<li>博通剛剛提高了其股息——但這並不是唯一一個顯示出強勁信號的公司</li>
</ul>
<p>其他幾家機構投資者也對該股票的持倉進行了調整。IMG Wealth Management Inc.在第二季度將其在雅培的股份增加了 759.1%。IMG Wealth Management Inc.現在擁有 189 股這家醫療產品製造商的股票，價值 26,000 美元，此前在該期間又購買了 167 股。Anfield Capital Management LLC 在第二季度將其在雅培的持股增加了 81.3%。Anfield Capital Management LLC 現在擁有 232 股這家醫療產品製造商的股票，價值 32,000 美元，此前在上個季度又購買了 104 股。Delos Wealth Advisors LLC 在第二季度購買了雅培的新頭寸，價值 32,000 美元。Curio Wealth LLC 在第二季度將其在雅培的股份提高了 15,250.0%。Curio Wealth LLC 現在擁有 307 股這家醫療產品製造商的股票，估值為 42,000 美元，此前在上個季度又購買了 305 股。最後，Pineridge Advisors LLC 在第二季度將其在雅培的持倉提高了 34.6%。Pineridge Advisors LLC 現在擁有 315 股這家醫療產品製造商的股票，價值 43,000 美元，此前在該期間又購買了 81 股。當前 75.18% 的股票由機構投資者持有。</p>
<h2>華爾街分析師觀點</h2>
<p>ABT 已經成為幾份分析師報告的主題。Jefferies Financial Group 在 10 月 16 日的研究報告中將雅培的目標股價從 145.00 美元提高至 149.00 美元，並給予該公司 “買入” 評級。BTIG Research 在 11 月 20 日的研究報告中重申了 “買入” 評級，並對雅培的股票設定了 145.00 美元的目標價。加拿大皇家銀行在 10 月 16 日的研究報告中重申了 “跑贏大盤” 評級，並設定了 147.00 美元的目標價。Benchmark 在 10 月 10 日的報告中開始覆蓋雅培。他們對該股票給予了 “買入” 評級，並設定了 145.00 美元的目標價。最後，富國銀行在 10 月 16 日的報告中將雅培的目標價從 142.00 美元提高至 146.00 美元，並給予該股票 “超配” 評級。兩位投資分析師對該股票給予了強烈買入評級，十七位給予了買入評級，四位給予了持有評級。根據 MarketBeat 的數據，該股票目前的平均評級為 “適度買入”，平均目標價為 147.00 美元。</p>
<ul>
<li>ABBV 股票：250 美元可能是大 Q3 財報後新的底線</li>
</ul>
<p><strong>獲取我們最新的 ABT 股票報告</strong></p>
<h2>雅培股票下跌 0.4%</h2>
<p>NYSE:ABT 的股票在週四開盤時為 125.30 美元。雅培的 52 周低點為 110.86 美元，52 周高點為 141.23 美元。該公司的市值為 2178.8 億美元，市盈率為 15.70，市盈增長比率為 2.29，貝塔值為 0.72。該公司的債務股本比為 0.23，速動比率為 1.24，流動比率為 1.70。該公司的 50 日移動平均線為 126.06 美元，200 日移動平均線為 129.72 美元。</p>
<ul>
<li>雅培在十月的價格暴跌是買入的信號</li>
</ul>
<p>雅培（NYSE:ABT - 獲取免費報告）在 10 月 15 日星期三發佈了其季度財報。這家醫療產品製造商報告該季度每股收益為 1.30 美元，符合市場共識預期的 1.30 美元。雅培的股本回報率為 17.60%，淨利潤率為 31.88%。該公司在該季度的收入為 113.7 億美元，而市場共識預期為 114 億美元。去年同期，該公司每股收益為 1.21 美元。雅培該季度的收入同比增長 6.9%。雅培已將其 2025 財年的指引設定為每股收益 5.120-5.180 美元。分析師平均預測雅培在當前財年將發佈每股收益 5.14 美元。</p>
<h2>雅培增加股息</h2>
<p>該公司最近還披露了一項季度股息，將於 2 月 13 日星期五支付。1 月 15 日星期四的股東將獲得 0.63 美元的股息。這比雅培之前的季度股息 0.59 美元有所增加。這代表着每年 2.52 美元的股息和 2.0% 的股息收益率。該股息的除息日期為 1 月 15 日星期四。雅培的派息比率目前為 29.57%。</p>
<h2>雅培公司簡介</h2>
<p>（免費報告）</p>
<p>雅培是一家全球醫療保健公司，總部位於伊利諾伊州的雅培公園，開發、製造和銷售廣泛的醫療產品和服務。雅培成立於 1888 年，通過多個業務領域運營，專注於診斷、醫療設備、營養品和成熟藥品。該公司向醫院、診所、實驗室、零售商和直接面向消費者的渠道提供旨在診斷、治療和管理各種健康狀況的產品。</p>
<p>在診斷方面，雅培提供實驗室和現場檢測平台及試劑，用於檢測傳染病、慢性疾病和生物標誌物；其 Alinity 系列儀器和快速檢測解決方案就是這一能力的例子。</p>
<h2>特色文章</h2>
<ul>
<li>我們更看好的五隻股票，勝過雅培</li>
<li>這個假期你花 1 美元能買到的最佳商品</li>
<li>假期驚喜：1 美元讓你擁有一切</li>
<li>美國 “最糟糕” 的聖誕促銷</li>
<li>市場恐慌：特朗普剛剛對你的股票投下了一顆炸彈</li>
<li>你家族的財富在 2026 年到期？</li>
</ul>
<p><strong>想看看其他對雅培持有股份的對沖基金嗎？</strong> 訪問 HoldingsChannel.com 獲取雅培（NYSE:ABT - 免費報告）的最新 13F 文件和內部交易信息。</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUFCVA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUFCVA"/></p>
<p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，旨在為讀者提供最快的報道和公正的覆蓋。請將任何問題或意見發送至 contact@marketbeat.com。</em></p>
<h2>你現在應該投資 1,000 美元在雅培嗎？</h2>
<p>在考慮雅培之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已經識別出五隻頂級分析師悄悄建議客户現在購買的股票，以便在更廣泛的市場注意到之前... 而雅培並不在名單上。</p>
<p>雖然雅培目前在分析師中獲得了中等買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

雅培

<p>Merit Financial Group LLC 在第三季度將其在雅培（NYSE:ABT）的持股增加了 32.7%，額外購買了 20,035 股，總持股達到 81,264 股，價值 1,088 萬美元。其他機構投資者也顯著增加了他們的持倉。分析師對雅培持樂觀態度，普遍評級為 “適度買入”，平均目標價為 147.00 美元。雅培的股票開盤價為 125.30 美元，52 周區間為 110.86 美元至 141.23 美元。該公司報告第三季度每股收益為 1.30 美元，符合預期，並已將 2025 財年的指導目標設定為每股收益 5.120-5.180 美元</p>

<p>Merit Financial Group LLC lifted its holdings in shares of Abbott Laboratories (NYSE:ABT - Free Report) by 32.7% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 81,264 shares of the healthcare product maker's stock after purchasing an additional 20,035 shares during the quarter. Merit Financial Group LLC's holdings in Abbott Laboratories were worth $10,884,000 as of its most recent SEC filing.</p>
<div class="lb-trans"><p>Merit Financial Group LLC 在最近向證券交易委員會的披露中表示，在第三季度將其在雅培（NYSE:ABT - 免費報告）股票的持有量提高了 32.7%。該公司在季度內購買了 20,035 股後，持有 81,264 股這家醫療產品製造商的股票。根據其最近的 SEC 文件，Merit Financial Group LLC 在雅培的持股價值為 10,884,000 美元。</p>
</div><p>Get <strong>Abbott Laboratories</strong> alerts:</p>
<div class="lb-trans"><p>獲取 <strong>雅培</strong> 的提醒：</p>
</div><ul>
<li>Broadcom Just Raised Its Dividend—But It’s Not the Only One Signaling Strength</li>
</ul>
<div class="lb-trans"><ul>
<li>博通剛剛提高了其股息——但這並不是唯一一個顯示出強勁信號的公司</li>
</ul>
</div><p>Several other institutional investors have also made changes to their positions in the stock. IMG Wealth Management Inc. increased its stake in Abbott Laboratories by 759.1% during the 2nd quarter. IMG Wealth Management Inc. now owns 189 shares of the healthcare product maker's stock worth $26,000 after acquiring an additional 167 shares during the period. Anfield Capital Management LLC grew its holdings in shares of Abbott Laboratories by 81.3% during the 2nd quarter. Anfield Capital Management LLC now owns 232 shares of the healthcare product maker's stock worth $32,000 after purchasing an additional 104 shares in the last quarter. Delos Wealth Advisors LLC bought a new position in shares of Abbott Laboratories in the second quarter worth $32,000. Curio Wealth LLC raised its stake in Abbott Laboratories by 15,250.0% in the second quarter. Curio Wealth LLC now owns 307 shares of the healthcare product maker's stock valued at $42,000 after purchasing an additional 305 shares in the last quarter. Finally, Pineridge Advisors LLC lifted its position in Abbott Laboratories by 34.6% during the second quarter. Pineridge Advisors LLC now owns 315 shares of the healthcare product maker's stock worth $43,000 after purchasing an additional 81 shares during the period. 75.18% of the stock is currently owned by institutional investors.</p>
<div class="lb-trans"><p>其他幾家機構投資者也對該股票的持倉進行了調整。IMG Wealth Management Inc.在第二季度將其在雅培的股份增加了 759.1%。IMG Wealth Management Inc.現在擁有 189 股這家醫療產品製造商的股票，價值 26,000 美元，此前在該期間又購買了 167 股。Anfield Capital Management LLC 在第二季度將其在雅培的持股增加了 81.3%。Anfield Capital Management LLC 現在擁有 232 股這家醫療產品製造商的股票，價值 32,000 美元，此前在上個季度又購買了 104 股。Delos Wealth Advisors LLC 在第二季度購買了雅培的新頭寸，價值 32,000 美元。Curio Wealth LLC 在第二季度將其在雅培的股份提高了 15,250.0%。Curio Wealth LLC 現在擁有 307 股這家醫療產品製造商的股票，估值為 42,000 美元，此前在上個季度又購買了 305 股。最後，Pineridge Advisors LLC 在第二季度將其在雅培的持倉提高了 34.6%。Pineridge Advisors LLC 現在擁有 315 股這家醫療產品製造商的股票，價值 43,000 美元，此前在該期間又購買了 81 股。當前 75.18% 的股票由機構投資者持有。</p>
</div><h2>Wall Street Analyst Weigh In</h2>
<div class="lb-trans"><h2>華爾街分析師觀點</h2>
</div><p>ABT has been the subject of several analyst reports. Jefferies Financial Group boosted their target price on shares of Abbott Laboratories from $145.00 to $149.00 and gave the company a &#34;buy&#34; rating in a research report on Thursday, October 16th. BTIG Research reissued a &#34;buy&#34; rating and issued a $145.00 price objective on shares of Abbott Laboratories in a research note on Thursday, November 20th. Royal Bank Of Canada restated an &#34;outperform&#34; rating and set a $147.00 target price on shares of Abbott Laboratories in a research note on Thursday, October 16th. Benchmark initiated coverage on Abbott Laboratories in a report on Friday, October 10th. They issued a &#34;buy&#34; rating and a $145.00 target price on the stock. Finally, Wells Fargo &amp; Company boosted their price target on Abbott Laboratories from $142.00 to $146.00 and gave the stock an &#34;overweight&#34; rating in a report on Thursday, October 16th. Two investment analysts have rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and four have given a Hold rating to the stock. According to MarketBeat, the stock currently has an average rating of &#34;Moderate Buy&#34; and an average price target of $147.00.</p>
<div class="lb-trans"><p>ABT 已經成為幾份分析師報告的主題。Jefferies Financial Group 在 10 月 16 日的研究報告中將雅培的目標股價從 145.00 美元提高至 149.00 美元，並給予該公司 “買入” 評級。BTIG Research 在 11 月 20 日的研究報告中重申了 “買入” 評級，並對雅培的股票設定了 145.00 美元的目標價。加拿大皇家銀行在 10 月 16 日的研究報告中重申了 “跑贏大盤” 評級，並設定了 147.00 美元的目標價。Benchmark 在 10 月 10 日的報告中開始覆蓋雅培。他們對該股票給予了 “買入” 評級，並設定了 145.00 美元的目標價。最後，富國銀行在 10 月 16 日的報告中將雅培的目標價從 142.00 美元提高至 146.00 美元，並給予該股票 “超配” 評級。兩位投資分析師對該股票給予了強烈買入評級，十七位給予了買入評級，四位給予了持有評級。根據 MarketBeat 的數據，該股票目前的平均評級為 “適度買入”，平均目標價為 147.00 美元。</p>
</div><ul>
<li>ABBV Stock: $250 May Be the New Floor After Big Q3 Earnings Beat</li>
</ul>
<div class="lb-trans"><ul>
<li>ABBV 股票：250 美元可能是大 Q3 財報後新的底線</li>
</ul>
</div><p><strong>Get Our Latest Stock Report on ABT</strong></p>
<div class="lb-trans"><p><strong>獲取我們最新的 ABT 股票報告</strong></p>
</div><h2>Abbott Laboratories Stock Down 0.4%</h2>
<div class="lb-trans"><h2>雅培股票下跌 0.4%</h2>
</div><p>Shares of NYSE:ABT opened at $125.30 on Thursday. Abbott Laboratories has a 52-week low of $110.86 and a 52-week high of $141.23. The company has a market capitalization of $217.88 billion, a PE ratio of 15.70, a price-to-earnings-growth ratio of 2.29 and a beta of 0.72. The company has a debt-to-equity ratio of 0.23, a quick ratio of 1.24 and a current ratio of 1.70. The company has a fifty day moving average of $126.06 and a 200-day moving average of $129.72.</p>
<div class="lb-trans"><p>NYSE:ABT 的股票在週四開盤時為 125.30 美元。雅培的 52 周低點為 110.86 美元，52 周高點為 141.23 美元。該公司的市值為 2178.8 億美元，市盈率為 15.70，市盈增長比率為 2.29，貝塔值為 0.72。該公司的債務股本比為 0.23，速動比率為 1.24，流動比率為 1.70。該公司的 50 日移動平均線為 126.06 美元，200 日移動平均線為 129.72 美元。</p>
</div><ul>
<li>Abbott Laboratories' October Price Plunge Is a Signal to Buy</li>
</ul>
<div class="lb-trans"><ul>
<li>雅培在十月的價格暴跌是買入的信號</li>
</ul>
</div><p>Abbott Laboratories (NYSE:ABT - Get Free Report) last released its quarterly earnings data on Wednesday, October 15th. The healthcare product maker reported $1.30 earnings per share for the quarter, meeting the consensus estimate of $1.30. Abbott Laboratories had a return on equity of 17.60% and a net margin of 31.88%.The company had revenue of $11.37 billion for the quarter, compared to the consensus estimate of $11.40 billion. During the same quarter last year, the business posted $1.21 EPS. Abbott Laboratories's revenue for the quarter was up 6.9% on a year-over-year basis. Abbott Laboratories has set its FY 2025 guidance at 5.120-5.180 EPS. On average, equities analysts predict that Abbott Laboratories will post 5.14 EPS for the current fiscal year.</p>
<div class="lb-trans"><p>雅培（NYSE:ABT - 獲取免費報告）在 10 月 15 日星期三發佈了其季度財報。這家醫療產品製造商報告該季度每股收益為 1.30 美元，符合市場共識預期的 1.30 美元。雅培的股本回報率為 17.60%，淨利潤率為 31.88%。該公司在該季度的收入為 113.7 億美元，而市場共識預期為 114 億美元。去年同期，該公司每股收益為 1.21 美元。雅培該季度的收入同比增長 6.9%。雅培已將其 2025 財年的指引設定為每股收益 5.120-5.180 美元。分析師平均預測雅培在當前財年將發佈每股收益 5.14 美元。</p>
</div><h2>Abbott Laboratories Increases Dividend</h2>
<div class="lb-trans"><h2>雅培增加股息</h2>
</div><p>The company also recently disclosed a quarterly dividend, which will be paid on Friday, February 13th. Stockholders of record on Thursday, January 15th will be paid a $0.63 dividend. This is an increase from Abbott Laboratories's previous quarterly dividend of $0.59. This represents a $2.52 annualized dividend and a dividend yield of 2.0%. The ex-dividend date of this dividend is Thursday, January 15th. Abbott Laboratories's payout ratio is currently 29.57%.</p>
<div class="lb-trans"><p>該公司最近還披露了一項季度股息，將於 2 月 13 日星期五支付。1 月 15 日星期四的股東將獲得 0.63 美元的股息。這比雅培之前的季度股息 0.59 美元有所增加。這代表着每年 2.52 美元的股息和 2.0% 的股息收益率。該股息的除息日期為 1 月 15 日星期四。雅培的派息比率目前為 29.57%。</p>
</div><h2>Abbott Laboratories Profile</h2>
<div class="lb-trans"><h2>雅培公司簡介</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免費報告）</p>
</div><p>Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.</p>
<div class="lb-trans"><p>雅培是一家全球醫療保健公司，總部位於伊利諾伊州的雅培公園，開發、製造和銷售廣泛的醫療產品和服務。雅培成立於 1888 年，通過多個業務領域運營，專注於診斷、醫療設備、營養品和成熟藥品。該公司向醫院、診所、實驗室、零售商和直接面向消費者的渠道提供旨在診斷、治療和管理各種健康狀況的產品。</p>
</div><p>In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.</p>
<div class="lb-trans"><p>在診斷方面，雅培提供實驗室和現場檢測平台及試劑，用於檢測傳染病、慢性疾病和生物標誌物；其 Alinity 系列儀器和快速檢測解決方案就是這一能力的例子。</p>
</div><h2>Featured Articles</h2>
<div class="lb-trans"><h2>特色文章</h2>
</div><ul>
<li>Five stocks we like better than Abbott Laboratories</li>
<li>The Best $1 You'll Spend This Holiday Season</li>
<li>Holiday surprise: $1 gets you everything</li>
<li>America’s “most deplorable” Christmas sale</li>
<li>Market Panic: Trump Just Dropped a Bomb on Your Stocks</li>
<li>Your family's wealth expires in 2026?</li>
</ul>
<div class="lb-trans"><ul>
<li>我們更看好的五隻股票，勝過雅培</li>
<li>這個假期你花 1 美元能買到的最佳商品</li>
<li>假期驚喜：1 美元讓你擁有一切</li>
<li>美國 “最糟糕” 的聖誕促銷</li>
<li>市場恐慌：特朗普剛剛對你的股票投下了一顆炸彈</li>
<li>你家族的財富在 2026 年到期？</li>
</ul>
</div><p><strong>Want to see what other hedge funds are holding ABT?</strong> Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Abbott Laboratories (NYSE:ABT - Free Report).</p>
<div class="lb-trans"><p><strong>想看看其他對雅培持有股份的對沖基金嗎？</strong> 訪問 HoldingsChannel.com 獲取雅培（NYSE:ABT - 免費報告）的最新 13F 文件和內部交易信息。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUFCVA" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NYSE&amp;Symbol=ABT"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，旨在為讀者提供最快的報道和公正的覆蓋。請將任何問題或意見發送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Abbott Laboratories Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1,000 美元在雅培嗎？</h2>
</div><p>Before you consider Abbott Laboratories, you'll want to hear this.</p>
<div class="lb-trans"><p>在考慮雅培之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Abbott Laboratories wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已經識別出五隻頂級分析師悄悄建議客户現在購買的股票，以便在更廣泛的市場注意到之前... 而雅培並不在名單上。</p>
</div><p>While Abbott Laboratories currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然雅培目前在分析師中獲得了中等買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

Merit Financial Group LLC 收購了雅培實驗室 20,035 股股票 $ABT